Ikarian Capital, LLC Celldex Therapeutics, Inc. Call Options Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $9.79 Million - $13.6 Million	305,500 New	305,500 $10.4 Million
Q2 2022 Aug 12, 2022	BUY	$20.5 - $37.33 $3.33 Million - $6.06 Million	162,400 Added 47.2%	506,500 $13.7 Million
Q1 2022 May 13, 2022	SELL	$27.64 - $39.32 $6.9 Million - $9.82 Million	-249,700 Reduced 42.05%	344,100 $11.7 Million
Q4 2021 Feb 14, 2022	SELL	$35.68 - $56.27 $7.06 Million - $11.1 Million	-197,800 Reduced 24.99%	593,800 $22.9 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $5.55 Million - $10.7 Million	191,600 Added 31.93%	791,600 $42.7 Million
Q2 2021 Aug 16, 2021	BUY	$20.71 - $35.37 $2 Million - $3.41 Million	96,500 Added 19.17%	600,000 $20.1 Million
Q1 2021 May 17, 2021	BUY	$16.19 - $29.91 $1.68 Million - $3.1 Million	103,500 Added 25.87%	503,500 $10.4 Million
Q4 2020 Feb 12, 2021	BUY	$14.99 - $22.75 $5.04 Million - $7.65 Million	336,200 Added 526.96%	400,000 $7.01 Million
Q3 2020 Nov 16, 2020	SELL	$9.65 - $15.19 $2.03 Million - $3.2 Million	-210,700 Reduced 76.76%	63,800 $946,000
Q2 2020 Aug 14, 2020	BUY	$1.61 - $13.41 $441,945 - $3.68 Million	274,500 New	274,500 $3.57 Million

203

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.06B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.